<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; ICMR</title>
	<atom:link href="http://www.tapanray.in/tag/icmr/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Changing Doctors’ Practice Dynamics With Covid-19 And Beyond</title>
		<link>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=changing-doctors-practice-dynamics-with-covid-19-and-beyond</link>
		<comments>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/#comments</comments>
		<pubDate>Mon, 11 May 2020 00:00:24 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[connected]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[detailing]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[dynamic]]></category>
		<category><![CDATA[face-to-face]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Outbreak]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[practice]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10067</guid>
		<description><![CDATA[Unexpectedly, the answer to an onerous question surfaced just around a year’s time. In my article on this blog, written on April 08, 2019, I raised a question &#8211; “Would ‘Connected Healthcare’ Catch Pharma Players Off-Guard?” Interestingly, an unexpected and abrupt turn of &#8230; <a href="http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/changing-doctors-practice-dynamics-with-covid-19-and-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Antimicrobial Resistance: A Recent Perspective</title>
		<link>http://www.tapanray.in/antimicrobial-resistance-a-recent-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=antimicrobial-resistance-a-recent-perspective</link>
		<comments>http://www.tapanray.in/antimicrobial-resistance-a-recent-perspective/#comments</comments>
		<pubDate>Mon, 19 Feb 2018 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[AMF]]></category>
		<category><![CDATA[AMR]]></category>
		<category><![CDATA[antibiotic]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[Antimicrobial]]></category>
		<category><![CDATA[chemists]]></category>
		<category><![CDATA[Davos]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[FDCs]]></category>
		<category><![CDATA[foundation]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[initiatives]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resistance]]></category>
		<category><![CDATA[retail]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[unapproved]]></category>
		<category><![CDATA[UNGA]]></category>
		<category><![CDATA[WEF]]></category>
		<category><![CDATA[World Economic Forum]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8798</guid>
		<description><![CDATA[On January 23, 2018, at the World Economic Forum in Davos, Switzerland – the first independent analysis of pharmaceutical industry efforts to tackle antibiotic drug resistance, was published by the Netherlands based Access to Medicine Foundation. The issue of Antimicrobial &#8230; <a href="http://www.tapanray.in/antimicrobial-resistance-a-recent-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/antimicrobial-resistance-a-recent-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cancer Care: Dawns A New Era Of Precision Medicine In India</title>
		<link>http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=cancer-care-dawns-a-new-era-of-precision-medicine-in-india</link>
		<comments>http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/#comments</comments>
		<pubDate>Mon, 22 Aug 2016 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[biomarker]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[dawn]]></category>
		<category><![CDATA[diagnostics]]></category>
		<category><![CDATA[era]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[one-size-fits-all]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Pharmacogenomics]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7779</guid>
		<description><![CDATA[The concept of ‘Precision Medicine’ has started gaining increasing importance, in the treatment process of many serious diseases, such as cancer. It is now happening in many countries of the world, including India. The National Institutes of Health (NIH) of &#8230; <a href="http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/cancer-care-dawns-a-new-era-of-precision-medicine-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India To Expand NLEM 2011: A Step In The Right Direction</title>
		<link>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-to-expand-nlem-2011-a-step-in-the-right-direction</link>
		<comments>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/#comments</comments>
		<pubDate>Mon, 11 May 2015 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2002]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2014-15]]></category>
		<category><![CDATA[2015-16]]></category>
		<category><![CDATA[Ananth Kumar]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[direction]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[Expansion]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Katoch]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[Lok Sabha]]></category>
		<category><![CDATA[Margaret Chan]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[public health foundation]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[Supreme Court]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[union budget]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6591</guid>
		<description><![CDATA[Responding to growing discontentment on the flawed National List of Essential Medicines 2011 (NLEM 2011) and equally vociferous demand for its urgent rectification, on May 5, 2015, in a written reply to the Lower House of Indian Parliament (Lok Sabha) &#8230; <a href="http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Would ‘Regenerative Medicine’ Shape The Future Of Global Healthcare?</title>
		<link>http://www.tapanray.in/would-regenerative-medicine-shape-the-future-of-global-healthcare/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=would-regenerative-medicine-shape-the-future-of-global-healthcare</link>
		<comments>http://www.tapanray.in/would-regenerative-medicine-shape-the-future-of-global-healthcare/#comments</comments>
		<pubDate>Mon, 22 Dec 2014 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[Chiesi Farmaceutici]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Embryonic]]></category>
		<category><![CDATA[European Medicine Agency]]></category>
		<category><![CDATA[Holoclar]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Limbal]]></category>
		<category><![CDATA[LSCD]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regenerative medicine]]></category>
		<category><![CDATA[Reliance]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Shankara netralaya]]></category>
		<category><![CDATA[stem cells]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Type I]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6274</guid>
		<description><![CDATA[Just the last week, on December 19, 2014, international media broke the news of regulatory approval of the first stem cell treatment by the European Medicines Agency (EMA). The Agency reportedly has recommended an Orphan Drug &#8211; Holoclar of the &#8230; <a href="http://www.tapanray.in/would-regenerative-medicine-shape-the-future-of-global-healthcare/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/would-regenerative-medicine-shape-the-future-of-global-healthcare/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>R&amp;D: Is Indian Pharma Moving Up the Value Chain?</title>
		<link>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rd-is-indian-pharma-moving-up-the-value-chain</link>
		<comments>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/#comments</comments>
		<pubDate>Mon, 02 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[analogue]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[Cadilla]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[Dr]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[dyslipidemia]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[falciparum]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glitazar]]></category>
		<category><![CDATA[hibernation]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[lab]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lipaglyn]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[mass]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[plasmodium]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy's]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Rotavac]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Synrium]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Torrent]]></category>
		<category><![CDATA[universities]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3530</guid>
		<description><![CDATA[It almost went unnoticed by many, when in the post product patent regime, Ranbaxy launched its first homegrown ‘New Drug’ of India, Synriam, on April 25, 2012, coinciding with the ‘World Malaria Day’. The drug is used in the treatment &#8230; <a href="http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Deadly ‘Superbugs’: The larger issues</title>
		<link>http://www.tapanray.in/deadly-superbugs-the-larger-issues/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deadly-superbugs-the-larger-issues</link>
		<comments>http://www.tapanray.in/deadly-superbugs-the-larger-issues/#comments</comments>
		<pubDate>Mon, 11 Apr 2011 00:30:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Deadly]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[larger]]></category>
		<category><![CDATA[ministry of health]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[MRSA]]></category>
		<category><![CDATA[NDM1]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Superbugs]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=277</guid>
		<description><![CDATA[Every year, April 7 is observed as ‘World Health Day’ across the globe. This year, 2011, is no exception. However, interestingly considering the increasing debate on the antibiotic resistance ‘Superbug’, the theme of this year has been very aptly coined &#8230; <a href="http://www.tapanray.in/deadly-superbugs-the-larger-issues/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deadly-superbugs-the-larger-issues/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
